Bruker Corporation (NASDAQ:BRKR) announced a quarterly dividend on Monday, August 14th, Wall Street Journal reports. Investors of record on Tuesday, September 5th will be paid a dividend of 0.04 per share by the medical research company on Friday, September 22nd. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Thursday, August 31st.

Shares of Bruker Corporation (NASDAQ:BRKR) opened at 28.35 on Friday. The firm has a market capitalization of $4.50 billion, a PE ratio of 28.27 and a beta of 1.10. Bruker Corporation has a 52 week low of $19.58 and a 52 week high of $30.22. The company’s 50 day moving average price is $28.35 and its 200-day moving average price is $25.99.

Bruker Corporation (NASDAQ:BRKR) last issued its earnings results on Thursday, August 3rd. The medical research company reported $0.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The company had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a return on equity of 26.66% and a net margin of 9.65%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the business posted $0.20 EPS. On average, equities research analysts expect that Bruker Corporation will post $1.12 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Bruker Corporation (BRKR) To Go Ex-Dividend on August 31st” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/26/bruker-corporation-brkr-to-go-ex-dividend-on-august-31st.html.

Bruker Corporation declared that its board has initiated a share repurchase plan on Friday, May 12th that authorizes the company to buyback $225.00 million in shares. This buyback authorization authorizes the medical research company to buy shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board believes its shares are undervalued.

In other news, Director Richard Kniss sold 24,000 shares of the stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $28.23, for a total transaction of $677,520.00. Following the sale, the director now owns 46,753 shares in the company, valued at $1,319,837.19. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Frank H. Laukien purchased 2,335 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were purchased at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the acquisition, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at $1,035,106,062.54. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 117,624 shares of company stock worth $3,271,574. Corporate insiders own 35.20% of the company’s stock.

An institutional investor recently raised its position in Bruker Corporation stock. The Manufacturers Life Insurance Company boosted its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 7.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,003 shares of the medical research company’s stock after buying an additional 331 shares during the period. The Manufacturers Life Insurance Company ‘s holdings in Bruker Corporation were worth $144,000 as of its most recent filing with the SEC. 66.44% of the stock is currently owned by institutional investors and hedge funds.

BRKR has been the topic of several recent analyst reports. Zacks Investment Research raised shares of Bruker Corporation from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Thursday, July 6th. Barclays PLC reaffirmed an “equal weight” rating and issued a $30.00 price target (up previously from $26.00) on shares of Bruker Corporation in a report on Monday, July 17th. Wells Fargo & Company cut shares of Bruker Corporation from a “market perform” rating to an “underperform” rating in a report on Wednesday, July 12th. Cowen and Company reaffirmed a “hold” rating and issued a $29.00 price target on shares of Bruker Corporation in a report on Friday, July 14th. Finally, BidaskClub cut shares of Bruker Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Bruker Corporation currently has an average rating of “Hold” and a consensus price target of $27.00.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Dividend History for Bruker Corporation (NASDAQ:BRKR)

Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.